(Total Views: 844)
Posted On: 07/24/2020 5:26:03 PM
Post# of 148917
Re: clambottler #44886
WHERE Is the Goal Post Currently
Where is the Goal Post
In the most recent trial release of information, Leronlimab PII
At least one SAE ( Serious Adverse Event ) was reported in 5 patients (5/56; 8.9%) receiving leronlimab.
While At least one SAE was reported in 6 patients (6/28; 21.4%) receiving placebo.
However, for a simple comparison, The placebo arm, was enrolled at ½ the # of patients as the Leronlimab arm. So Simply put, for consideration in trial comparison, that could then be also stated as SAEs were reported in 12 patients ( 12/56 )
Leronlimab Placebo
5/56 12/56
So it is perhaps fair to state, less than ½ as many patients on Leronlimab Suffered a Serious Adverse Event.
Because of the 2 to 1 trial enrollment, perhaps the general public did not catch that. In a broad stroke sort of look, It certainly seems to be significant.
In the mild to moderates not really sure where the goal post is, I don't see any claims to it, Leronlimab may have just set a goal post we shall soon find out.
So how low is the hurdle in SEVERE patients ?
Where is the goal post currently ?
Remembering GILD’s drug REMB simply had no survival benefit at all, but did claim to get patients released from hospital 4 or 5 days early
The best or second best so far then appears to be dexamethasone:
https://apnews.com/89d963958b042cc921e64ab3eff5a74d
The article claims: " Researchers estimated that the drug would prevent one death for every eight patients treated while on breathing machines
and one for every 25 patients on extra oxygen alone. "
"The survival benefit is clear and large in those patients who are sick enough to require oxygen treatment, so dexamethasone should now become standard of care in these patients. "
So it seems if the Leronlimab patients get out of bed 6 days earlier in the severe trial, or Leronlimab may prevent 2 deaths for every eight patients in the severe trial, they might just become the new leader in the severe population.
It certainly is interesting to learn about this drug and the human body. Lets hope for the patients and their families the Leronlimab drug does well. It may be our best bet currently. Seems to be.
.
.
.
Where is the Goal Post
In the most recent trial release of information, Leronlimab PII
At least one SAE ( Serious Adverse Event ) was reported in 5 patients (5/56; 8.9%) receiving leronlimab.
While At least one SAE was reported in 6 patients (6/28; 21.4%) receiving placebo.
However, for a simple comparison, The placebo arm, was enrolled at ½ the # of patients as the Leronlimab arm. So Simply put, for consideration in trial comparison, that could then be also stated as SAEs were reported in 12 patients ( 12/56 )
Leronlimab Placebo
5/56 12/56
So it is perhaps fair to state, less than ½ as many patients on Leronlimab Suffered a Serious Adverse Event.
Because of the 2 to 1 trial enrollment, perhaps the general public did not catch that. In a broad stroke sort of look, It certainly seems to be significant.
In the mild to moderates not really sure where the goal post is, I don't see any claims to it, Leronlimab may have just set a goal post we shall soon find out.
So how low is the hurdle in SEVERE patients ?
Where is the goal post currently ?
Remembering GILD’s drug REMB simply had no survival benefit at all, but did claim to get patients released from hospital 4 or 5 days early
The best or second best so far then appears to be dexamethasone:
https://apnews.com/89d963958b042cc921e64ab3eff5a74d
The article claims: " Researchers estimated that the drug would prevent one death for every eight patients treated while on breathing machines
and one for every 25 patients on extra oxygen alone. "
"The survival benefit is clear and large in those patients who are sick enough to require oxygen treatment, so dexamethasone should now become standard of care in these patients. "
So it seems if the Leronlimab patients get out of bed 6 days earlier in the severe trial, or Leronlimab may prevent 2 deaths for every eight patients in the severe trial, they might just become the new leader in the severe population.
It certainly is interesting to learn about this drug and the human body. Lets hope for the patients and their families the Leronlimab drug does well. It may be our best bet currently. Seems to be.
.
.
.
(4)
(0)Scroll down for more posts ▼
